FDA
-
-
-
-
-
-
-
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
-
-
-
-
-
-
-
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
-
-
-
-
-
-
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
-
-
-
-
-
-
-
Alcon (ALC) to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
-
-
-
-
-
-
-
New Alcon Innovations in Intraocular Lenses, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meeting
-
-
-
-
-
-
-
Alcon Announces European Launch of Vivity, the Only Presbyopia-correcting Intraocular Lens With X-WAVE Technology
-
-
-
-
-
-
-
Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19
-
322,222 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

